S
Sherry Y. Wu
Researcher at University of Texas MD Anderson Cancer Center
Publications - 83
Citations - 6194
Sherry Y. Wu is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Cancer & Ovarian cancer. The author has an hindex of 37, co-authored 82 publications receiving 4662 citations. Previous affiliations of Sherry Y. Wu include University of Queensland & Princess Alexandra Hospital.
Papers
More filters
Journal ArticleDOI
Advances and Challenges of Liposome Assisted Drug Delivery.
Lisa Sercombe,Tejaswi Veerati,Tejaswi Veerati,Fatemeh Moheimani,Sherry Y. Wu,Anil K. Sood,Susan Hua +6 more
TL;DR: The advances in liposome assisted drug delivery, biological challenges that still remain, and current clinical and experimental use of liposomes for biomedical applications are discussed.
Journal ArticleDOI
Tumour angiogenesis regulation by the miR-200 family
Chad V. Pecot,Rajesha Rupaimoole,Da Yang,Rehan Akbani,Cristina Ivan,Chunhua Lu,Sherry Y. Wu,Hee Dong Han,Maitri Y. Shah,Cristian Rodriguez-Aguayo,Justin Bottsford-Miller,Yuexin Liu,Sang Bae Kim,Anna K. Unruh,Vianey Gonzalez-Villasana,Huang L,Behrouz Zand,Myrthala Moreno-Smith,Lingegowda S. Mangala,Morgan Taylor,Heather J. Dalton,Vasudha Sehgal,Yunfei Wen,Yu Kang,Keith A. Baggerly,Ju Seog Lee,Prahlad T. Ram,Murali Ravoori,Vikas Kundra,Xinna Zhang,Rouba Ali-Fehmi,Ana M. Gonzalez-Angulo,Pierre P. Massion,George A. Calin,Gabriel Lopez-Berestein,Wei Zhang,Anil K. Sood +36 more
TL;DR: A difference in clinical outcome is demonstrated based on miR-200's role in blocking tumour angiogenesis, defined as its utility as a potential therapeutic agent in a cancer-dependent context.
Journal ArticleDOI
Hematogenous Metastasis of Ovarian Cancer: Rethinking Mode of Spread
Sunila Pradeep,Seung W. Kim,Sherry Y. Wu,Masato Nishimura,Pradeep Chaluvally-Raghavan,Takahito Miyake,Chad V. Pecot,Sun Jin Kim,Hyun Jin Choi,Farideh Z. Bischoff,J. A. Mayer,Li Huang,Alpa M. Nick,Carolyn S. Hall,Cristian Rodriguez-Aguayo,Behrouz Zand,Heather J. Dalton,Thiruvengadam Arumugam,Ho-Jeong Lee,Hee Dong Han,Hee Dong Han,Min Soon Cho,Rajesha Rupaimoole,Lingegowda S. Mangala,Vasudha Sehgal,Sang Cheul Oh,Sang Cheul Oh,Jinsong Liu,Ju Seog Lee,Robert L. Coleman,Prahlad T. Ram,Gabriel Lopez-Berestein,Isaiah J. Fidler,Anil K. Sood +33 more
TL;DR: A parabiosis model is used that demonstrates preferential hematogenous metastasis of ovarian cancer to the omentum and reveals that the ErbB3-neuregulin 1 (NRG1) axis is a dominant pathway responsible for hematogeneous omental metastasis.
Journal ArticleDOI
RNAi Therapies: Drugging the Undruggable
TL;DR: Recent advances in small interfering RNA delivery and target selection provide unprecedented opportunities for clinical translation and present strategies for making RNAi-based therapy a viable part of cancer management.
Journal ArticleDOI
Lipidic Systems for In Vivo siRNA Delivery
Sherry Y. Wu,Nigel A.J. McMillan +1 more
TL;DR: This review presents a comprehensive overview of the barriers and recent progress for both local and systemic delivery of therapeutic siRNA using lipidic vectors and current advances in the targeted delivery of siRNA and their impacts on the field of RNA interference (RNAi)-based therapy.